Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Onofrj, M ^a   Bonanni, L ^a   De Angelis, M V ^a   Anzellotti, F ^a   Ciccocioppo, F ^a   Thomas, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Parkinson's disease; Pharmacokinetics; Ropinirole

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; ROPINIROLE; DELAYED RELEASE FORMULATION; INDOLE DERIVATIVE;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FAT INTAKE; FATIGUE; FOOD; FOOD DRUG INTERACTION; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICAL TECHNOLOGY; MOTOR DYSFUNCTION; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ADMINISTRATION AND DOSAGE; ANIMAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DYSKINESIA, DRUG-INDUCED; HALF LIFE TIME; METABOLISM; PHARMACOKINETICS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; DELAYED-ACTION PREPARATIONS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HALF-LIFE; HUMANS; INDOLES; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 72649094248     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70842-9     Document Type: Article

References (23)

1. Blanchet P.J., Calon F., Martel J.C., Bédard P.J., Di Paolo T., Walters R.R., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272 (1995) 854-859
2. Poewe W. Treatments for Parkinson disease - past achievements and current clinical needs. Neurology 72 7 Suppl (2009) S65-S73
3. Wiseman L.R., and Fitton A. Cabergoline: a review of its efficacy in the treatment of Parkinson's disease. CNS Drugs 12 (1999) 485-497
4. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 (2004) 733-746
5. Baas H.K., and Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 46 Suppl 1 (2001) 18-23
6. Antonini A., and Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6 (2007) 826-829
7. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 21 (2006) 1844-1850
8. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Bertoni J., et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49 (1997) 393-399 Erratum in:
9. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Bertoni J., et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49 (1997) 1484
10. Lieberman A., Olanow C.W., Sethi K., Swanson P., Waters C.H., Fahn S., et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51 (1998) 1057-1062 Erratum in: Neurology 1999;52:435.
11. Hauser R.A., Rascol O., Korczyn A.D., Jon Stoessl A., Watts R.L., Poewe W., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 (2007) 2409-2417
12. Conte U., and Maggi L. Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drugs of different solubility. Biomaterials 17 (1996) 889-896
13. Tompson D.J., and Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 29 (2007) 2654-2666
14. Stocchi F., Hersh B.P., Scott B.L., Nausieda P.A., Giorgi L., and Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24 (2008) 2883-2895
15. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68 (2007) 1108-1115
16. Watts R.L., Sethi K.D., Pawha R., Adams B.E., and Earl N.L. Ropinirole 24-hour prolonged-release delays the onset of dyskinesia compared with carbidopa/levodopa in patients with Parkinson's disease treated with levodopa. Mov Disord 22 Suppl 16 (2007) S95
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised ed. DHEW Publication No. ADM 76-338. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 218-22.
18. Beck A.T., Steer R.A., and Brown G.K. BDI-II manual (1996), The Psychological Corporation, London
19. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 (1991) 540-545
20. Chaudhuri K.R., Pal S., DiMarco A., Whately-Smith C., Bridgman K., Mathew R., et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 73 (2002) 629-635
21. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 284 (2000) 1931-1938
22. Tompson D., and Oliver-Willwong R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. Clin Neuropharmacol 32 (2009) 140-148
23. Peto V., Jenkinson C., and Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 245 Suppl 1 (1998) S10-S14